EU Legislative Review Needs To ‘Fix The Ecosystem’ For ATMPs
Executive Summary
Developers of advanced therapies say the European Commission must do more to address the “hospital exemption” and the regulation of advanced therapy medicinal products as genetically modified organisms.
You may also be interested in...
EU Sets New Date For Publication Of Delayed Pharma Revision Proposals
Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.
EU Sets New Date For Publication Of Delayed Pharma Revision Proposals
Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.
Expanding Hospital Exemptions For ATMPs Could Make Europe Less Attractive To Investors
The forthcoming overhaul of the EU pharma legislation should not include an expansion of the hospital exemption provision for advanced therapies, warn industry and regulators.